Laura is the Senior Director of Antibody Sciences at Adimab and the Chief Scientific Officer and a co-founder of Adagio Therapeutics. Her team at Adimab is focused on understanding human B cell responses to viral infection and discovering broadly neutralizing antibodies to a wide variety of emerging viral pathogens, including Ebola, Zika, yellow fever, and SARS-CoV-2. At Adagio, Laura oversees a broad portfolio of research in the area of viral immunology, including the identification of potent and broadly neutralizing antibodies to advance into clinical development. Prior to joining Adimab in 2012, Laura earned her Ph.D. in Immunology and Microbiology in Dennis Burton’s laboratory at The Scripps Research Institute and completed a post-doctoral research fellowship in Immunology at The University of California-San Francisco. Laura has received multiple fellowships and awards, including the Endpoints News “The 20 under 40 in biopharma” award in 2020.
Learn more about the James S. Huston Antibody Science Talent Award.